Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media

Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated for the treatment of immunological diseases. However, the animal-derived growth supplements utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative media formulations is imperative for MSC therapeutic application. Human BMMSC and AdMSC were expanded in media supplemented with either human platelet lysates (HPL), serum-free media/xeno-free FDA-approved culture medium (SFM/XF), or fetal bovine serum (FBS) and the effects on their properties were investigated. The immunophenotype of resting and IFN-γ primed BMMSC and AdMSC remained unaltered in all media. Both HPL and SFM/XF increased the proliferation of BMMSC and AdMSC. Expansion of BMMSC and AdMSC in HPL increased their differentiation, compared to SFM/XF and FBS. Resting BMMSC and AdMSC, expanded in FBS or SFM/XF, demonstrated potent immunosuppressive properties in both non-primed and IFN-γ primed conditions, whereas HPL-expanded MSC exhibited diminished immunosuppressive properties. Finally, IFN-γ primed BMMSC and AdMSC expanded in SFM/XF and HPL expressed attenuated levels of IDO-1 compared to FBS. Herein, we provide strong evidence supporting the use of the FDA-approved SFM/XF medium, in contrast to the HPL medium, for the expansion of MSC towards therapeutic applications.

[1]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[2]  R. Walker,et al.  Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. , 1997, Blood.

[3]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[4]  C. Suschek,et al.  Expansion of Adipose Mesenchymal Stromal Cells is Affected by Human Platelet Lysate and Plating Density , 2011, Cell transplantation.

[5]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[6]  M. Zenke,et al.  Donor Age of Human Platelet Lysate Affects Proliferation and Differentiation of Mesenchymal Stem Cells , 2012, PloS one.

[7]  M. Vemuri,et al.  Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. , 2009, Cytotherapy.

[8]  N. Kulagina,et al.  Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. , 1974, Experimental hematology.

[9]  A. Ignatius,et al.  Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components , 2012, Cytotherapy.

[10]  Antal Rot,et al.  Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions , 2004, Platelets.

[11]  Joelle Dulong,et al.  Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. , 2013, Stem cells and development.

[12]  H. Bourne,et al.  Mechanisms of inflammation , 1974, Clinical pharmacology and therapeutics.

[13]  W. Fibbe,et al.  Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders , 2012, Annals of the New York Academy of Sciences.

[14]  Jeffrey A Jones,et al.  Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma, , 2010 .

[15]  A. Caplan,et al.  Mesenchymal stem cells: mechanisms of inflammation. , 2011, Annual review of pathology.

[16]  Wolfgang Wagner,et al.  Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. , 2014, Cytotherapy.

[18]  A. Mackensen,et al.  Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells , 2000, Cancer Immunology, Immunotherapy.

[19]  A. Cometa,et al.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors , 2009, Haematologica.

[20]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[21]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  D. G. Halme,et al.  FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[23]  D. Hommes,et al.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study , 2010, Gut.

[24]  O. Kilian,et al.  Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. , 2004, European journal of medical research.

[25]  M. Vemuri,et al.  A novel serum-free medium for the expansion of human mesenchymal stem cells , 2010, Stem Cell Research & Therapy.

[26]  J. Laine,et al.  N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.

[27]  M. Richard,et al.  Mesenchymal stem cells induce apoptosis of activated T cells , 2005, Leukemia.

[28]  D. Hommes,et al.  Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. , 2008, Journal of Crohn's & colitis.

[29]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[30]  Uma Lakshmipathy,et al.  Development and Characterization of a Clinically Compliant Xeno‐Free Culture Medium in Good Manufacturing Practice for Human Multipotent Mesenchymal Stem Cells , 2012, Stem cells translational medicine.

[31]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[32]  A. Cometa,et al.  Ex vivo expansion of mesenchymal stromal cells. , 2011, Best practice & research. Clinical haematology.

[33]  D. Hommes,et al.  Pretreatment with Interferon‐γ Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of Colitis , 2011, Stem cells.

[34]  O. Ringdén,et al.  Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. , 2006, Current opinion in immunology.

[35]  Y. Ishii,et al.  Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. , 2009, Biochemical and biophysical research communications.

[36]  D. Strunk,et al.  Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.

[37]  D. García-Olmo,et al.  Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. , 2008, Expert opinion on biological therapy.

[38]  A. Dietz,et al.  Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability , 2011, Cell transplantation.

[39]  O. Ringdén,et al.  No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.

[40]  Andrej-Nikolai Spiess,et al.  Accelerated and safe expansion of human mesenchymal stromal cells in animal serum‐free medium for transplantation and regenerative medicine , 2007, Journal of cellular physiology.

[41]  L. Isola,et al.  Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  T. Burnouf,et al.  Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion , 2014, New Biotechnology.

[43]  Mimmi Patrikoski,et al.  Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells , 2013, Stem Cell Research & Therapy.

[44]  Franco Locatelli,et al.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. , 2007, Blood.

[45]  L. Moretta,et al.  Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and function , 2011, European journal of immunology.

[46]  D. Strunk,et al.  Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. , 2009, Journal of visualized experiments : JoVE.

[47]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[48]  R. Schneider,et al.  Human platelet lysate gel provides a novel three dimensional-matrix for enhanced culture expansion of mesenchymal stromal cells. , 2012, Tissue engineering. Part C, Methods.

[49]  D. Strunk,et al.  Immunomodulative Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells Cultured in Human Platelet Lysate , 2011, Journal of Clinical Immunology.

[50]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[51]  L. Muul,et al.  Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. , 2002, Human gene therapy.